International Clinical Trial: A single-arm, single-center, Phase II clinical study on neoadjuvant treatment of resectable non-small cell lung cancer with evoximab combined with Lukang and saltuzumab

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119732) titled 'A single-arm, single-center, Phase II clinical study on neoadjuvant treatment of resectable non-small cell lung cancer with evoximab combined with Lukang and saltuzumab' on March 3.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The Second Affiliated Hospital of Air Force Military Medical University

Condition: Non-small cell lung cancer

Intervention: Single-Arm Group:This study adopts the Simon two-stage optimal design. In the first stage, 16 subjects will be enrolled. If pCR is observed in more than 3 of the 16 subjects, the study will proceed to the second stage and continue ...